---
title: "PharmaCyte Biotech surges 14% during regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302890119.md"
description: "PharmaCyte Biotech rose 14.23% to US$0.3998. Up 17.52% over five sessions and down 44.78% YTD."
datetime: "2026-10-23T13:40:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302890119.md)
  - [en](https://longbridge.com/en/news/302890119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302890119.md)
generator: "portal-rs"
---

# PharmaCyte Biotech surges 14% during regular trading

PharmaCyte Biotech (PMCB.US) surged more than **14%** during regular trading to **$0.3998**.

The stock is up 17.52% over the past five sessions and down 44.78% year to date. The intraday swing reached 16.34%.

The Nasdaq Composite is down 0.91% over the past five sessions and up 11.44% year to date.

The company recently disclosed material weaknesses related to insufficient segregation of duties for the chief financial officer and inadequate management review controls.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [PMCB.US](https://longbridge.com/en/quote/PMCB.US.md)

## Related News & Research

- [PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue](https://longbridge.com/en/news/294264310.md)
- [AEHR: Record $33.0m quarter; FY27 revenue outlook raised to $150m on strong AI demand](https://longbridge.com/en/news/304010185.md)
- [Is SpaceX Stock Worth Buying While It's Below $140?](https://longbridge.com/en/news/304084857.md)
- [Palantir Q3 revenue jumps 96%, beats analyst expectations](https://longbridge.com/en/news/304009150.md)
- [BUZZ-Oracle tumbles on $20 bln stock-and-bonds sale to fund AI ambitions](https://longbridge.com/en/news/304111417.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**